Tg Therapeutics (TGTX) Minority Interest (2011 - 2012)

Tg Therapeutics' (TGTX) quarterly Minority Interest came in at $8.5 million in Q3 2012, down 2.83% quarter-over-quarter from $8.8 million in Q2 2012.

Tg Therapeutics (TGTX) Minority Interest (2011 - 2012) Analysis & Trends

Tg Therapeutics' Minority Interest history runs 2 years deep, the most recent figure standing at $8.5 million for Q3 2012.

On a quarterly basis, Minority Interest changed N/A year-over-year to $8.5 million in Q3 2012; TTM through Sep 2012 was $8.5 million, a N/A change from a year earlier, with the FY2012 full-year figure at $9.4 million, changed N/A from the prior year.
Minority Interest eased to $8.5 million in Q3 2012 per TGTX's latest filing, from $8.8 million in the prior quarter.
Across five years, Minority Interest topped out at $9.4 million in Q1 2012 and bottomed at $11681.0 in Q4 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Tg Therapeutics	8.88 Bn	8.80 Bn	171.41 Mn

Download Data